Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • velu
    Junior Member
    • Sep 2015
    • 4

    with cufflinks, can there be "0" fpkm value and yet full read support?

    Hi,
    I used hisat2 (2.0.5) to map 150b Paired-end reads on to the draft genome of castorbean and used cufflinks (version 2.2.1) to perform reference annotation based transcript assembly (RABT). This data is NOT for differential expression analysis. The assembler reported novel isoforms and some novel genes. From the results, of the transcripts that were as present in the gtf file used for RABT, some had an FPKM value of "0.0000000000" but were "yes" for "full_read_support" whereas the rest that were "yes" for "full_read_support" carried an FPKM value at 1 or above.
    Could anyone please explain why would a transcript be described as present with "full_read_support," yet with an FPKM value of "0.0000000000?"

    Thanks.
  • Dario1984
    Senior Member
    • Jun 2011
    • 166

    #2
    I have noticed similar problems with Cufflinks in the past. Our research group no longer uses it because it hasn't been updated in 3 years and some of the FPKM values look suspicious, which you have noticed.

    Comment

    • velu
      Junior Member
      • Sep 2015
      • 4

      #3
      Thank you, Dario1984.
      Then, what method do you follow for the assembly of reads that do not have such limitations?

      Comment

      • Dario1984
        Senior Member
        • Jun 2011
        • 166

        #4
        We use Trinity because we found its results can be experimentally validated by biologists. There's also a genome guided assembly mode. It was developed a few years ago, but it still maintained by the developer. You might also be interested in categorising your assembled transcripts with TransDecoder.

        Comment

        • velu
          Junior Member
          • Sep 2015
          • 4

          #5
          Thank you.
          I will go through the possibilities you have suggested.

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
            by SEQadmin2


            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

            The systematic characterization of the human proteome has
            ...
            07-20-2026, 11:48 AM
          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            07-08-2026, 05:17 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 07-24-2026, 12:17 PM
          0 responses
          26 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-23-2026, 11:41 AM
          0 responses
          21 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-20-2026, 11:10 AM
          0 responses
          210 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-13-2026, 10:26 AM
          0 responses
          78 views
          0 reactions
          Last Post SEQadmin2  
          Working...